Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?

Background and Objectives: This investigation aimed to determine the impacts of concurrent proton pump inhibitors (PPIs) on progression-free survival (PFS) in patients with hormone receptor-positive and HER2-negative metastatic breast cancer managed with palbociclib or ribociclib as either the initi...

Descripción completa

Detalles Bibliográficos
Autores principales: Odabas, Hatice, Dogan, Akif, Ozcelik, Melike, Yildirim, Sedat, Ozkerim, Ugur, Turan, Nedim, Yildirim, Mahmut Emre, Gumus, Mahmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052377/
https://www.ncbi.nlm.nih.gov/pubmed/36984558
http://dx.doi.org/10.3390/medicina59030557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052377/
https://www.ncbi.nlm.nih.gov/pubmed/36984558
http://dx.doi.org/10.3390/medicina59030557

Ejemplares similares